PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of acgcaserepsLink to Publisher's site
 
ACG Case Rep J. 2017; 4: e112.
Published online 2017 October 11. doi:  10.14309/crj.2017.112
PMCID: PMC5636906

Checkpoint Inhibitor–Induced Colitis: A New Type of Inflammatory Bowel Disease?

Abstract

Checkpoint inhibitors are immune-stimulatory antibodies that have transformed the management and prognosis of individuals with metastatic melanoma and other cancers. Checkpoint inhibitor–induced colitis is an increasingly recognized immune-related adverse event that shares many of the same phenotypical, serological, and histological characteristics of both Crohn’s disease and ulcerative colitis, suggesting that checkpoint inhibitor–induced colitis may represent a new inflammatory bowel disease phenotype. We report a 73-year-old man with metastatic melanoma who developed ipilimumab-induced colitis with subsequent transformation to Crohn?s colitis-like phenotype after the addition of pembrolizumab.


Articles from ACG Case Reports Journal are provided here courtesy of American College of Gastroenterology